Generic Drug User Fee Projections Complicated By Shifting Personnel Costs
Executive Summary
After dialing back the inflation adjustment in GDUFA II, FDA’s ANDA review program now faces rising personnel costs, in contrast to the agency overall, suggesting that GDUFA III might need a more tailored formula.
You may also be interested in...
US FDA Aims To Speed Communications On Cell And Gene Therapy Issues With Q&A Guidance
Advocates also call for reauthorization negotiations to be open to the public during meeting on the PDUFA VII commitment letter.
FDA Rebates Biosimilar Fees And Limits Generic Fee Hike
The generic drug user fee could have jumped substantially to ensure operating reserves were sufficient, but the FDA decided against it, and biosimilar program reserves were too high, so the agency reduced the amount it will need.
US FDA Rebates Biosimilar Fees, Limits Generic Fee Hike In FY 2022
The generic drug user fee could have jumped substantially to ensure operating reserves were sufficient, but the FDA decided against it, and biosimilar program reserves were too high, so the agency reduced the amount it will need.